These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 28176879)

  • 1. PARP inhibitor increases chemosensitivity by upregulating miR-664b-5p in BRCA1-mutated triple-negative breast cancer.
    Song W; Tang L; Xu Y; Xu J; Zhang W; Xie H; Wang S; Guan X
    Sci Rep; 2017 Feb; 7():42319. PubMed ID: 28176879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells.
    Marijon H; Lee DH; Ding L; Sun H; Gery S; de Gramont A; Koeffler HP
    Biomed Pharmacother; 2018 Mar; 99():543-551. PubMed ID: 29902865
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decreased miR-206 expression in BRCA1 wild-type triple-negative breast cancer cells after concomitant treatment with gemcitabine and a Poly(ADP-ribose) polymerase-1 inhibitor.
    Sasaki A; Tsunoda Y; Tsuji M; Udaka Y; Oyamada H; Tsuchiya H; Oguchi K
    Anticancer Res; 2014 Sep; 34(9):4893-7. PubMed ID: 25202071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effects of Olaparib, a PARP-1 Inhibitor, on Triple Negative Breast Cancer Cells with a BRCA1 Mutation].
    Tsunoda Y; Sasaki A; Sakamoto N; Haruyama Y; Nashimoto M; Koshida Y; Fukuma E
    Gan To Kagaku Ryoho; 2021 Jan; 48(1):53-56. PubMed ID: 33468723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigation of BRCAness associated miRNA-gene axes in breast cancer: cell-free miR-182-5p as a potential expression signature of BRCAness.
    Darbeheshti F; Kadkhoda S; Keshavarz-Fathi M; Razi S; Bahramy A; Mansoori Y; Rezaei N
    BMC Cancer; 2022 Jun; 22(1):668. PubMed ID: 35715772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. miR-638 mediated regulation of BRCA1 affects DNA repair and sensitivity to UV and cisplatin in triple-negative breast cancer.
    Tan X; Peng J; Fu Y; An S; Rezaei K; Tabbara S; Teal CB; Man YG; Brem RF; Fu SW
    Breast Cancer Res; 2014 Sep; 16(5):435. PubMed ID: 25228385
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MicroRNA-582-5p promotes triple-negative breast cancer invasion and metastasis by antagonizing CMTM8.
    Zeng X; Ma X; Guo H; Wei L; Zhang Y; Sun C; Han N; Sun S; Zhang N
    Bioengineered; 2021 Dec; 12(2):10126-10135. PubMed ID: 34978519
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer.
    Johnson SF; Cruz C; Greifenberg AK; Dust S; Stover DG; Chi D; Primack B; Cao S; Bernhardy AJ; Coulson R; Lazaro JB; Kochupurakkal B; Sun H; Unitt C; Moreau LA; Sarosiek KA; Scaltriti M; Juric D; Baselga J; Richardson AL; Rodig SJ; D'Andrea AD; Balmaña J; Johnson N; Geyer M; Serra V; Lim E; Shapiro GI
    Cell Rep; 2016 Nov; 17(9):2367-2381. PubMed ID: 27880910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MicroRNA-211-5p suppresses tumour cell proliferation, invasion, migration and metastasis in triple-negative breast cancer by directly targeting SETBP1.
    Chen LL; Zhang ZJ; Yi ZB; Li JJ
    Br J Cancer; 2017 Jun; 117(1):78-88. PubMed ID: 28571042
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MicroRNA deregulation in triple negative breast cancer reveals a role of miR-498 in regulating BRCA1 expression.
    Matamala N; Vargas MT; González-Cámpora R; Arias JI; Menéndez P; Andrés-León E; Yanowsky K; Llaneza-Folgueras A; Miñambres R; Martínez-Delgado B; Benítez J
    Oncotarget; 2016 Apr; 7(15):20068-79. PubMed ID: 26933805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sequential targeting of PARP with carboplatin inhibits primary tumour growth and distant metastasis in triple-negative breast cancer.
    Beniey M; Hubert A; Haque T; Cotte AK; Béchir N; Zhang X; Tran-Thanh D; Hassan S
    Br J Cancer; 2023 May; 128(10):1964-1975. PubMed ID: 36941406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. miR-17-5p suppresses cell proliferation and invasion by targeting ETV1 in triple-negative breast cancer.
    Li J; Lai Y; Ma J; Liu Y; Bi J; Zhang L; Chen L; Yao C; Lv W; Chang G; Wang S; Ouyang M; Wang W
    BMC Cancer; 2017 Nov; 17(1):745. PubMed ID: 29126392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suppressive role exerted by microRNA-29b-1-5p in triple negative breast cancer through SPIN1 regulation.
    Drago-Ferrante R; Pentimalli F; Carlisi D; De Blasio A; Saliba C; Baldacchino S; Degaetano J; Debono J; Caruana-Dingli G; Grech G; Scerri C; Tesoriere G; Giordano A; Vento R; Di Fiore R
    Oncotarget; 2017 Apr; 8(17):28939-28958. PubMed ID: 28423652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MiRNA-20a-5p promotes the growth of triple-negative breast cancer cells through targeting RUNX3.
    Bai X; Han G; Liu Y; Jiang H; He Q
    Biomed Pharmacother; 2018 Jul; 103():1482-1489. PubMed ID: 29864933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. mTOR Inhibitors Suppress Homologous Recombination Repair and Synergize with PARP Inhibitors via Regulating SUV39H1 in BRCA-Proficient Triple-Negative Breast Cancer.
    Mo W; Liu Q; Lin CC; Dai H; Peng Y; Liang Y; Peng G; Meric-Bernstam F; Mills GB; Li K; Lin SY
    Clin Cancer Res; 2016 Apr; 22(7):1699-712. PubMed ID: 26546619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CDK inhibition results in pharmacologic BRCAness increasing sensitivity to olaparib in BRCA1-WT and olaparib resistant in Triple Negative Breast Cancer.
    Orhan E; Velazquez C; Tabet I; Fenou L; Rodier G; Orsetti B; Jacot W; Sardet C; Theillet C
    Cancer Lett; 2024 May; 589():216820. PubMed ID: 38574883
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthetic Lethality Exploitation by an Anti-Trop-2-SN-38 Antibody-Drug Conjugate, IMMU-132, Plus PARP Inhibitors in
    Cardillo TM; Sharkey RM; Rossi DL; Arrojo R; Mostafa AA; Goldenberg DM
    Clin Cancer Res; 2017 Jul; 23(13):3405-3415. PubMed ID: 28069724
    [No Abstract]   [Full Text] [Related]  

  • 18. miR-199a-5p confers tumor-suppressive role in triple-negative breast cancer.
    Chen J; Shin VY; Siu MT; Ho JC; Cheuk I; Kwong A
    BMC Cancer; 2016 Nov; 16(1):887. PubMed ID: 27842518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Using next-generation sequencing to redefine BRCAness in triple-negative breast cancer.
    Lin PH; Chen M; Tsai LW; Lo C; Yen TC; Huang TY; Chen CK; Fan SC; Kuo SH; Huang CS
    Cancer Sci; 2020 Apr; 111(4):1375-1384. PubMed ID: 31958182
    [TBL] [Abstract][Full Text] [Related]  

  • 20. miR-7-5p overexpression suppresses cell proliferation and promotes apoptosis through inhibiting the ability of DNA damage repair of PARP-1 and BRCA1 in TK6 cells exposed to hydroquinone.
    Luo H; Liang H; Chen Y; Chen S; Xu Y; Xu L; Liu J; Zhou K; Peng J; Guo G; Lai B; Song L; Yang H; Liu L; Peng J; Liu Z; Tang L; Chen W; Tang H
    Chem Biol Interact; 2018 Mar; 283():84-90. PubMed ID: 29421518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.